THE 60-SECOND GUIDE
Bradykinin
A natural signal—not a wellness treatment.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Bradykinin is a short-lived signal involved in inflammation, pain, blood-vessel widening, and swelling. Its effects help explain how the body responds to injury, but the same signaling can become harmful when excessive. This profile concerns a biological messenger rather than a wellness treatment. [1]
Potential benefits
Contributes to normal vascular regulation and inflammatory signaling. Pain signaling helps alert the body to injury. Its pathway led to major insights in cardiovascular pharmacology. [1]
Evidence & its limits
Human experiments demonstrate a blood-pressure effect, not a broad health benefit. In a small study of intravenous bradykinin , the pressure response differed between healthy participants and patients with renal hypertension, and captopril altered its potency. A measurable pathway effect is not evidence that increasing the signal is desirable. [1]
Risks & unknowns
Excess signaling can contribute to pain, swelling, low blood pressure, and angioedema. It helps explain some ACE-inhibitor cough and angioedema. It is not administered as a wellness peptide. [1]
Status & scope
A natural signaling molecule, not a wellness treatment. Human pathway experiments do not demonstrate a benefit from increasing bradykinin. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- Discovery history in PubMed
- Historical article
- Rocha e Silva et al.: original bradykinin report, 1949
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.